Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Incorrect as you have manipulated people's statements. I stated that Na Nose development was funded with millions of euros during development in Haicks lab.
I think the release is actually a good thing. Here's why:
1. They clearly now care about the share price and are no longer playing their game of... let it drop to 10 cents. Those days seem gone.
2. The developments they describe are actually interesting and signify they are working hard.
3. They say it's going to be ready for trial in 1 month. That's actually much closer than anyone expected, whether they actually start the trial or not (because it takes time to design as I have eluded to before), if they actually have the device ready, then I think we will see some SP jumps.
4. It signifies that if it's almost done for Cannabix, it's definitely almost done for Breathtec. Double the money to be made.
NB: I do not like how it took the share price dropping for them to put this out...
so they DOOOOOO care!
Desperation.
Pittcon is not going to do anything for this, because Pittcon doesn't OFFER anything new - any material updates of this publicly traded company are issued in monthly reports and press release. In fact, if you did your DD you would realize that Breathtec gave away a big hint in their last release and stated that THEY have made advances in FAIMS for disease detection, whereas Cannabix did not report such advance in theirs. And you can bet that if Cannabix saw gains they would have also.
End of the day, this is overvalued and Breathtec is WAY undervalued. Make smart investments folks. You get two devices for the price of one with the sister, and Na-NOSE is proven to work and is in trial testing. Furthermore, the share price is a quarter of BLO.
Last thing. If the company starts tweeting like crazy when the price drops... beware. Desperate. This is gonna drop hard tomorrow.
You should read the monthly report, there are developments they discuss that upon completion will warrant a PR. They provide timeline on those developments which coincide with my previous post.
They will announce location of the trial testing, as well as details of the lab they built, and furthermore, they will announce where progression/development stands.
He just pointed out that they stated that news of the trial was coming in "weeks" and it's been months and there is no news.
I don't see that as a bad thing (in retrospect) because it means news is coming soon.
Especially since we know that news is coming regarding Breathtecs new lab (likely in Vancouver) and the testing of the next version of FAIMS for Breathtec which apparently is completed and ready to go.
Advances to Breathtec FAIMS = advances to Cannabix FAIMS...
Lab built for Breathtec FAIMS = lab built for Cannabix FAIMS...
Lets make some serious money.
Nope, actually... The news release states that testing will be conducted in Canada. There is no proof that a lab has been built in Florida, investors should wonder where these facts come from. The monthly report states there is a new lab, not where. Don't leave too soon, it's time to make millions. Likely Breathtec will be coming North too. Na-NOSE is in Canada, why not FAIMS too.
October 19, 2016
Cannabix Technologies Develops Beta 2.0 Marijuana Breathalyzer
[...]
Scientific Testing for the FAIMS Cannabix Marijuana Breathalyzer
Cannabix scientists are formulating a scientific protocol to conduct live THC breath testing using the Beta 2.0 Cannabix Marijuana Breathalyzer in the coming weeks. The scientific testing will likely be conducted in Vancouver BC, Canada, where medical marijuana users will be engaged to determine the accuracy of the Beta 2.0 Cannabix Marijuana Breathalyzer to detect both smoked and edible consumption of marijuana in human breath. The results of the scientific tests will be used to prepare submissions for approval of the Cannabix Marijuana Breathalyzer as a court-approved device by the Minister of Justice in Canada and the National Highway and Safety Authority in the United States.
Pay attention to detail. Look at this: "Cannabix Technologies is working to develop a rigorous trial with expedited ethics approval to begin detailed scientific trial testing of the Cannabix Marijuana Breathalyzer. This trial is intended to compare the Cannabix Marijuana Breathalyzer utilizing breath samples with correlated blood samples. The Company plans to use key metrics and guidance from Drugs and Driving Committee (DDC), which is an advisory body to the Canadian Department of Justice on issues relating to drug-impaired driving and has been given a mandate to develop reports regarding drugs that are proposed for zero-tolerance and per se legislation, including cannabis/THC."
DDC is Canadian, safe to assume trial will be conducted in Canada.
When breathtec announces their laboratory and FAIMS stuff next week (or so) we will know what is happening with Cannabix, by association. Share price of each will climb.
Sounds familiar
Going to be interesting to see the budgets for Cannabix and Breathtec. Sounds like some laboratory developments. Lots of questions unanswered, but some massive potential for both.
What about his shares dumped in Nov/Dec?
Nobody trying to drive price down. Let's get the price up. Take a second and actually read the following.
Trial design.
I posted the below comments on the Cannabix board. Given that FAIMS is being used by both companies I think it's relevant. What's perhaps most noteworthy is that Breathtec has a unique set of challenges. It's a bonus that the two hour time frame for detection is not an issue (the issue of metabolism of the active compounds that we look for is not an issue, in the sense that they aren't present in the body in small quantities for fletting periods of time, rather, there is tons of build up and they are their chronically, i.e. chronic diseases).
Also, patient populations with the disease, display the same biomarkers, there is less variablity to control for (i.e. less "confounding").
The sensitivity and specificity of the FAIMS device are the ultimate parameters that will determine the devices success in the market. The sensitivity and specificity for that matter, are the most important parameters of any medical investigation. The good news is, the sensitivity is VERY high on FAIMS given detection in parts per billion, and the abundant biomarkers are often present in parts per million... easily detectable.
However, the higher the sensitivity (i.e. being able to detect at all), the lower the specificity (i.e. being able to choose the RIGHT compound). Similar to my mention of signal to noise below. For Breathtec, the specificity is like choosing the correct mountain in the mountain range. It's actually not that bad.
I think we will get VERY VERY good news in the next week or so regarding FAIMS and next stage testing.
My guess at trial design/next step:
In order to prove proof of concept, the trial designer must attempt to test one variable at a time with as many of the other variables as possible being held stable. If they do not isolate each factor, then the trial would be biased by "confounding variables". In lay terms, one of the inherent difficulties is that there are a few factors at play. It's not as simple as alcohol detection. Here's why:
1. The marijuana: People who smoke marijuana most of the time never weigh out the exact quantity, so it's often hard to know how much someone has smoked. The marijuana can come in a variety of different strains, each has varying potency (i.e. different quantities of the psychoaactive metabolite THC-9 + a variety of other chemical compounds which can confound). These extra compounds often how similar molecular weight and are going to show up on FAIMS detection with the same mass/charge ratio and thus appear in the same detection window. Lastly, often drug dealers lace there marijuana, and so someone may be high, but unless FAIMS ALSO simiultaneously detects other substances (like cocaine), then the device would underestimate how much has been smoked. Thus, these factors need to all be considered.
2. The human who smokes it: Each and every person will metabolize the marijuana at a different rate. The time frame for clearance is already tough to capture in the real world, because THC-9 is so potent, someone may still be high, but if being detected at 2 hours time since smoking, the quantity in the body can still be SUPER low. So you need ultra high detection capability. With high detection however, comes an unwanted picking up of all the other small chemical enzymes and biomarkers in breath which are useless (unless your Breathtec). Fourier transformation and multi-scan approaches can improve signal to noise, picking up less crap. Similar to in nuclear magnetic resonance spectrometry.
Take Home Points: So the key here is to tune the device to look in the right mass to charge detection window at the right time, for THC-9 specifically, and to use FAIMS and fourier transformation to get the good signal to noise (thus finding only the one THC signal). This all hinges on the assumption that THC-9 is the psychoactive compound the person has smoked. It doesn't control how much THC-9 was in the particular strain, nor how fast the user metabolizes. THUS, a good trial design would take several people, have them all smoke one strain of weed, check at various time intervals, then have the same group smoke another strain, check at various time intervals. Then use the same strain, and use different people and check at various time intervals. In each case, you can control one variable and check the others, decreasing confounding.
Yost and UFL won't be going anywhere. Cannabix and Breathtec need the expertise in how to continuously refine FAIMS. If something goes wrong, he needs to fix it.
What do you mean when you say "medical side" for testing? I'm not sure I understand.
I don't think they announced anything regarding FAIMS...? Maybe Na-NOSe.
GOOD FIND!!!!!!!!!!Sticky this. Clearly they didn't do their research and figure out it's a Canadian company. Nor did they contact management lol.
Nobody thinks Yost group is done. This party is just getting started.
It's not a bad thing. They have a chance to succeed in testing regardless of whether it's in Florida or not. I just think that if money can be saved by using FAIMS in Florida, then share with Breathtec.
lol. Well... they might...!
They may need to move to a different lab.
See red print.
Nano Lett. 2016 Jul 13;16(7):4194-202. doi: 10.1021/acs.nanolett.6b01066. Epub 2016 Jun 27.
Self-Healable Sensors Based Nanoparticles for Detecting Physiological Markers via Skin and Breath: Toward Disease Prevention via Wearable Devices.
Jin H1, Huynh TP, Haick H.
Author information
Abstract
Flexible and wearable electronic sensors are useful for the early diagnosis and monitoring of an individual's health state. Sampling of volatile organic compounds (VOCs) derived from human breath/skin or monitoring abrupt changes in heart-beat/breath rate should allow noninvasive monitoring of disease states at an early stage. Nevertheless, for many reported wearable sensing devices, interaction with the human body leads incidentally to unavoidable scratches and/or mechanical cuts and bring about malfunction of these devices. We now offer proof-of-concept of nanoparticle-based flexible sensor arrays with fascinating self-healing abilities. By integrating a self-healable polymer substrate with 5 kinds of functionalized gold nanoparticle films, a sensor array gives a fast self-healing (<3 h) and attractive healing efficiency in both the substrate and sensing films. The proposed platform was used in sensing pressure variation and 11 kinds of VOCs. The sensor array had satisfactory sensitivity, a low detection limit, and promising discrimination features in monitoring both of VOCs and pressure variation, even after full healing. These results presage a new type of smart sensing device, with a desirable performance in the possible detection and/or clinical application for a number of different purposes.
We know Breathtec is creating the new lab for testing either FAIMS or Na-NOSE. They say they have new avenues regarding infectious disease, which Na-NOSE is proven useful for. Thus, the new lab could be a Technoion extension in our homeland. However, that's a crystal ball theory. There are two sides to the coin - if we are talking about FAIMS, there is no reason to think that Cannabix and Breathtec won't be in their together. It's possible are legal barriers, but I doubt it. Becuase the technology is licensed to each for different purpose.
In fact, we know Breathtec and Cannabix have been using the same mass spectrometer all along. They are ridiculously expensive. Millions... so they haven't got a few. At least based on their financial documents. They say they have completed their first version of FAIMS (though we know that Cannabix has had a handheld for a while... and it's the same... so we really have known Breathtec has had one for a while too).
So yes, I think they will share costs and test on the same device. Because the device is the same.
I see the restructuring of the laboratory as a good thing. Shows that some form of positive development is taking place requiring an upgrade. This could be FAIMS, but likely could be Na-NOSE. While I agree the Cannabix testing could be done in the Breathtec lab (i.e. for FAIMS), this lab restructure could just be for Na-NOSE tech. Who knows.
Regardless, advance of one is advance of both. Putting money to good use.
Coin. Made me laugh.
I'll attend
Marijuana won't be legal in Canada for a while based on the most recent press. However, legality around public use and sale is different than trial testing in a controlled setting. It could be done anywhere with approval, however that hinges on a good trial design. Hopefully we will hear about that soon.
I look forward to hearing more about the new laboratory, and whether there are new Haick products in the pipeline.
Here's my final theory (unbiased, just a thought, no opinion).
Two companies are using the same mass spectrometer (FAIMS), in the same hand held form (the prototype(s)).
One company actively publishes news articles saying that they have made progress in producing a beta prototype (Cannabix). The other company (Breathtec) does not post anything related to production of a prototype (FAIMS), despite the prototype being the exact same.
You would expect the other company (Breathtec) to post something, given that they are using the same mass spectrometer as Cannabix, given Cannabix says it's built. And, they are detecting compounds that are EASIER to detect (abundant products of disease in breath which don't fade from the body like THC). In other words, if Cannabix has built the prototype, why hasn't Breathtec said they have it ready too... it's the same and if anything they should be further ahead.
This month the monthly reports state explicitly that Breathtec actually HAS developed a prototype, and in fact they are referring to a "VERSION 2". They state that they have set up a separate lab for testing.
My guess is that Breathtec can do their testing in Florida (no THC, no worries), so they needed a lab to do it there. Cannabix I think will have to conduct their trial elsewhere.
There is mention about an analytical laboratory that is SEPARATE from the UFL lab. Keep an eye on both companies postings. This laboratory might be the answer to all of our questions. The license is to the University of Florida technology, not Yost. Yost works for the UFL and the UFL by law owns FAIMS. That being said, Cannabix and Breathtec could be moving into a new lab, somewhere else (on or off campus), getting ready for "performance testing".
Shareholders deserve information. This is garbage that we don't know more. The company has a obligation to update us on the proceedings and material advances. I have emailed them and have no heard back.
I remain positive that the new laboratory is going to be the key.
Once we get trial news for FAIMS, things should turn around. A hint from either company will go a long way.
When I see a government approved trial, I will believe the device is ready. Because that means the government also believes it's ready for testing.
It's not about tactics or persuasion. It's about facts. Posters here have a hard time seeing that day trading and cashing in on the run ups is fair game, but that doesn't equal a solid company with a good product. The posters are quick to call someone who points negative pieces of information, persuasive or ill-intended. The long-view of the investment is completely grasped. Credibility holds no value. The ability to due DD and post it has value. Call the facts like you see them whether people like it or not. Suggesting Breathtec is ahead of Cannabix, being positive about one and calling out the other is not bipolar. Two companies deserve two opinions.
Answer: Yes.
Reason: They DID pump in November. The share price tripled on news of completing beta... which really holds no meaning. They show photos of a box, stating it's still being worked on. Three months later, still no trial and the monthly update says it's still be worked on.
Why did the stock his ~90's cents Canadian?
I can't find an answer. IMO it's not worth it's current value. This trades 4 times the price of BTH, and not only is their FAIMS further ahead in development, they also have a product in trial testing (approved trials at that).
So...
I know you don't like to hear that. Nobody ever does.
Look at the blue quote. The new initiative is liekly Na-NOSE related (infectious disease detection).
"The developmental testing of the latest FAIMS device is now completed"
They are "about to begin the performance testing of the V2 prototype which will be completed by the end of the month barring any technical issues."
They have "completed the set-up of our analytical laboratories. The new instrumentation located in the Company’s labs compliment the analytical equipment available at the University of Florida under our UF research contract resulting in significant resources available to conduct all of our scientific and clinical research."
"Management continues to finalize our 2017 budget which should be completed by mid-February. The budget includes all the activities associated with advancing both technologies through the end of 2017 as well as some new initiatives the company is conducting [/b]evaluating the potential use of our technology in the area of public health in preventing infectious diseases."
Well, take BTH for example. Management has done the following:
"The developmental testing of the latest FAIMS device is now completed and we are about to begin the performance testing of the V2 prototype which will be completed by the end of the month barring any technical issues. [...] The Company has completed the set-up of our analytical laboratories. The new instrumentation located in the Company’s labs compliment the analytical equipment available at the University of Florida under our UF research contract resulting in significant resources available to conduct all of our scientific and clinical research.
So if Cannabix only posts that their device is not yet complete, with no further detail, then you have to wonder.